Inspire Investing LLC Acquires New Holdings in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Inspire Investing LLC purchased 5,547 shares of Jazz Pharmaceuticals, valued at approximately $689,000, in the first quarter of the year.
• Recently, Jazz Pharmaceuticals reported an EPS of -$8.25 for the quarter, missing estimates, while revenues increased by 2.1% year-over-year.
• Analysts are generally optimistic about Jazz Pharmaceuticals, with fourteen giving it a buy rating and an average price target of $178.67.

Inspire Investing LLC bought a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 5,547 shares of the specialty pharmaceutical company's stock, valued at approximately $689,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JAZZ. Captrust Financial Advisors increased its position in Jazz Pharmaceuticals by 7.5% during the fourth quarter. Captrust Financial Advisors now owns 5,337 shares of the specialty pharmaceutical company's stock worth $657,000 after purchasing an additional 372 shares during the last quarter. Cetera Investment Advisers acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at about $1,243,000. Deutsche Bank AG increased its position in shares of Jazz Pharmaceuticals by 4.0% during the fourth quarter. Deutsche Bank AG now owns 16,012 shares of the specialty pharmaceutical company's stock valued at $1,972,000 after acquiring an additional 609 shares during the last quarter. Focus Partners Wealth acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at about $551,000. Finally, Nuveen Asset Management LLC increased its position in shares of Jazz Pharmaceuticals by 1.8% during the fourth quarter. Nuveen Asset Management LLC now owns 468,346 shares of the specialty pharmaceutical company's stock valued at $57,677,000 after acquiring an additional 8,448 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Up 0.5%

Shares of NASDAQ:JAZZ traded up $0.63 during trading on Thursday, hitting $130.17. 128,005 shares of the company were exchanged, compared to its average volume of 928,372. The stock has a market capitalization of $7.90 billion, a P/E ratio of -19.34, a PEG ratio of 7.85 and a beta of 0.24. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06. The firm's 50 day moving average price is $119.65 and its 200-day moving average price is $116.39.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $1.05 billion. During the same quarter last year, the company earned $5.30 EPS. The firm's revenue for the quarter was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the business's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the transaction, the director directly owned 429,973 shares of the company's stock, valued at approximately $55,303,127.26. The trade was a 1.38% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on JAZZ shares. Truist Financial lifted their price target on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a research report on Thursday, August 28th. Deutsche Bank Aktiengesellschaft started coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They set a "buy" rating and a $152.00 price target for the company. Needham & Company LLC reiterated a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. The Goldman Sachs Group lifted their price target on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a research report on Friday, August 29th. Finally, Zacks Research raised shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Friday, August 15th. Fourteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $178.67.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.